CRL Logo

Charles River Laboratories International Inc (CRL) Stock Forecast & Price Prediction

Live CRL Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Diagnostics & Research

$151.99

-1.18 (-0.77%)

12 Month Price Forecast For CRL

$151.99
Current Price
$7.77B
Market Cap
20 Ratings
Buy 5
Hold 12
Sell 3
Wall St Analyst Ratings

Distance to CRL Price Forecasts

+71.1%
To High Target of $260.12
+20.4%
To Median Target of $183.00
+0.0%
To Low Target of $152.00

CRL Price Momentum

-7.2%
1 Week Change
-12.6%
1 Month Change
-38.1%
1 Year Change
-17.7%
Year-to-Date Change
-44.7%
From 52W High of $275.00
+0.8%
From 52W Low of $150.79

๐Ÿค” Considering Charles River (CRL)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 12:59 PM UTC

CRL Analyst Ratings & Price Targets

Based on our analysis of 32 Wall Street analysts, CRL has a neutral consensus with a median price target of $183.00 (ranging from $152.00 to $260.12). The overall analyst rating is Buy (6.3/10). Currently trading at $151.99, the median forecast implies a 20.4% upside. This outlook is supported by 5 Buy, 12 Hold, and 3 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CRL Analyst Consensus

5
Buy
12
Hold
3
Sell

CRL Price Target Range

Low
$152.00
Average
$183.00
High
$260.12
Current: $151.99

Latest CRL Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CRL.

Date Firm Analyst Rating Change Price Target
Feb 5, 2025 Morgan Stanley Ricky Goldwasser Equal-Weight Maintains $184.00
Feb 3, 2025 JP Morgan Casey Woodring Neutral Maintains $175.00
Jan 23, 2025 Goldman Sachs Matthew Sykes Buy Maintains $190.00
Jan 22, 2025 William Blair Max Smock Market Perform Downgrade $0.00
Jan 17, 2025 UBS Dan Leonard Neutral Downgrade $185.00
Jan 14, 2025 William Blair Max Smock Outperform Reiterates $0.00
Dec 13, 2024 B of A Securities Derik De Bruin Neutral Maintains $210.00
Nov 11, 2024 TD Cowen Charles Rhyee Hold Maintains $227.00
Nov 7, 2024 UBS Dan Brennan Buy Maintains $250.00
Nov 7, 2024 Evercore ISI Group Ross Muken In-Line Maintains $225.00
Oct 23, 2024 CLSA Underperform Initiates $167.00
Oct 14, 2024 Redburn Atlantic Jamie Clark Sell Initiates $151.00
Oct 7, 2024 Evercore ISI Group Ross Muken In-Line Downgrade $190.00
Oct 2, 2024 B of A Securities Derik De Bruin Neutral Downgrade $215.00
Oct 1, 2024 Citigroup Patrick Donnelly Sell Downgrade $175.00
Sep 20, 2024 Baird Eric Coldwell Neutral Maintains $190.00
Aug 12, 2024 TD Cowen Charles Rhyee Hold Maintains $203.00
Aug 8, 2024 Barclays Luke Sergott Equal-Weight Maintains $210.00
Aug 8, 2024 Goldman Sachs Matthew Sykes Buy Maintains $250.00
Aug 8, 2024 Baird Eric Coldwell Neutral Downgrade $191.00

Stocks Similar to Charles River Laboratories International Inc

The following stocks are similar to Charles River based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Charles River Laboratories International Inc (CRL) Financial Data

Charles River Laboratories International Inc has a market capitalization of $7.77B with a P/E ratio of 19.0x. The company generates $4.06B in trailing twelve-month revenue with a 10.4% profit margin.

Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of +14.7% and return on equity of +11.9%.

Valuation Metrics

Market Cap $7.77B
Enterprise Value $10.37B
P/E Ratio 19.0x
PEG Ratio 14.8x
Price/Sales 1.9x

Growth & Margins

Revenue Growth (YoY) -1.6%
Gross Margin +34.6%
Operating Margin +14.7%
Net Margin +10.4%
EPS Growth -20.3%

Financial Health

Cash/Price Ratio +2.7%
Current Ratio 1.5x
Debt/Equity 72.2x
ROE +11.9%
ROA +4.8%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Charles River Laboratories International Inc logo

Charles River Laboratories International Inc (CRL) Company Overview

About Charles River Laboratories International Inc

What They Do

Provides drug discovery and safety testing services.

Business Model

The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. It generates revenue by selling research models and services, conducting preclinical drug discovery and safety assessments, and providing quality control testing for pharmaceuticals and consumer products.

Additional Information

Founded in 1947 and headquartered in Wilmington, Massachusetts, the company serves clients globally, including those in the United States, Europe, Canada, and the Asia Pacific. Its services support biopharmaceutical companies in drug development processes, making it a critical player in the healthcare and pharmaceutical industries.

Company Information

Sector

Healthcare

Industry

Diagnostics & Research

Employees

20,400

CEO

Mr. James C. Foster J.D.

Country

United States

IPO Year

2000

Charles River Laboratories International Inc (CRL) Latest News & Analysis

CRL stock latest news image
Quick Summary

Charles River (CRL) may not meet earnings expectations in its upcoming report due to lacking key factors for a potential earnings beat. Investors should prepare accordingly.

Why It Matters

Charles River's lack of key ingredients for an earnings beat may signal weaker performance, potentially impacting stock price and investor sentiment.

Source: Zacks Investment Research
Market Sentiment: Neutral
CRL stock latest news image
Quick Summary

Charles River and Deciphex are collaborating to enhance image management solutions and develop new AI tools for toxicologic pathology.

Why It Matters

Charles River and Deciphex's partnership in AI for toxicologic pathology signals innovation in biotech, potentially enhancing efficiency and accuracy in drug development, impacting market competitiveness.

Source: Business Wire
Market Sentiment: Neutral
CRL stock latest news image
Quick Summary

Charles River's fourth-quarter revenues are expected to benefit from growth in the Manufacturing and RMS segments.

Why It Matters

Increased growth in Manufacturing and RMS segments suggests strong performance for Charles River, potentially boosting revenue and impacting stock value positively.

Source: Zacks Investment Research
Market Sentiment: Positive
CRL stock latest news image
Quick Summary

Charles River Laboratories has scheduled its fourth-quarter 2024 earnings release and 2025 guidance conference call.

Why It Matters

Charles River Laboratories' upcoming earnings release and guidance can signal future performance, impacting stock valuation and investor sentiment. Market reactions may follow based on reported results.

Source: Business Wire
Market Sentiment: Neutral
CRL stock latest news image
Quick Summary

CRL has launched Apollo for CRADL, enhancing its technology integration across its portfolio.

Why It Matters

CRL's integration of Apollo into CRADL enhances its technology offerings, potentially improving efficiency and competitiveness, which can positively impact future revenue and stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
CRL stock latest news image
Quick Summary

Charles River has expanded its Apollo ecosystem to provide tailored client experiences that enhance data-driven decision-making.

Why It Matters

Charles River's expansion of the Apollo ecosystem enhances its service offerings, potentially increasing client retention and revenue, which could positively impact stock performance.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About CRL Stock

What is Charles River Laboratories International Inc's (CRL) stock forecast for 2025?

Based on our analysis of 32 Wall Street analysts, Charles River Laboratories International Inc (CRL) has a median price target of $183.00. The highest price target is $260.12 and the lowest is $152.00.

Is CRL stock a good investment in 2025?

According to current analyst ratings, CRL has 5 Buy ratings, 12 Hold ratings, and 3 Sell ratings. The stock is currently trading at $151.99. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CRL stock?

Wall Street analysts predict CRL stock could reach $183.00 in the next 12 months. This represents a 20.4% increase from the current price of $151.99. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Charles River Laboratories International Inc's business model?

The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. It generates revenue by selling research models and services, conducting preclinical drug discovery and safety assessments, and providing quality control testing for pharmaceuticals and consumer products.

What is the highest forecasted price for CRL Charles River Laboratories International Inc?

The highest price target for CRL is $260.12 from at , which represents a 71.1% increase from the current price of $151.99.

What is the lowest forecasted price for CRL Charles River Laboratories International Inc?

The lowest price target for CRL is $152.00 from at , which represents a 0.0% increase from the current price of $151.99.

What is the overall CRL consensus from analysts for Charles River Laboratories International Inc?

The overall analyst consensus for CRL is neutral. Out of 32 Wall Street analysts, 5 rate it as Buy, 12 as Hold, and 3 as Sell, with a median price target of $183.00.

How accurate are CRL stock price projections?

Stock price projections, including those for Charles River Laboratories International Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.